CoChat
Sign Up
Cited by 28

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?

Frohlich, Jan, Vinciguerra, Manlio·2020·GeroScience
DOI 10.1007/s11357-020-00279-w
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11357-020-00279-w

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 19 references

Research works printed but not linked: 315

  1. Jun J-I, Lau LF. Resolution of organ fibrosis. J Clin Invest. 128:97–107. · DOI
  2. Rosenbloom J. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010;152:159. · DOI
  3. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210. · DOI · Paper page
  4. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71:549–74. · DOI
  5. Thannickal VJ, Toews GB, White ES, Lynch JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395–417. · DOI
  6. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta. 2006;364:33–60. · DOI
  7. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Phys Cell Phys. 2013;304:C216–25. · DOI
  8. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500–3. · DOI · Paper page
  9. Karsdal MA, Manon-Jensen T, Genovese F, Kristensen JH, Nielsen MJ, Sand JMB, et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol-Gastrointest Liver Physiol Am Physiol Soc. 2015;308:G807–30.
  10. Rosenbloom J, Mendoza FA, Jimenez SA. Strategies for anti-fibrotic therapies. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2013;1832:1088–103. · DOI
  11. Thannickal VJ, Henke CA, Horowitz JC, Noble PW, Roman J, Sime PJ, et al. Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the National Heart, Lung, and Blood Institute. Am J Pathol. Elsevier. 2014;184:1643–51. · DOI
  12. Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123. https://doi.org/10.3389/fphar.2014.00123. · DOI · Paper page
  13. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314–21. · DOI · Paper page
  14. Anders H-J, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol JASN. 2011;22:1007–18. · DOI
  15. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006;7:774–8. · DOI
  16. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17:359–65. · DOI
  17. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776–87. · DOI
  18. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A. 1991;88:6642–6. · DOI · Paper page
  19. Nagaoka I, Trapnell BC, Crystal RG. Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. J Clin Invest. 1990;85:2023–7. · DOI
  20. Varga J, Jimenez SA. Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-β. Biochem Biophys Res Commun. 1986;138:974–80. · DOI
  21. Sandbo N, Dulin N. The actin cytoskeleton in myofibroblast differentiation: ultrastructure defining form and driving function. Transl Res. 2011;158:181–96. · DOI
  22. Desmoulière A. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol Int. 1995;19:471–6. · DOI
  23. Distler JHW, Györfi A-H, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol Nat. Publishing Group. 2019;15:705–30. · DOI
  24. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat M-L, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. Elsevier. 2007;170:1807–16. · DOI · Paper page
  25. McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem Cell Biol. 2007;39:666–71. · DOI
  26. Chen L-J, Ye H, Zhang Q, Li F-Z, Song L-J, Yang J, et al. Bleomycin induced epithelial-mesenchymal transition (EMT) in pleural mesothelial cells. Toxicol Appl Pharmacol. 2015;283:75–82. · DOI
  27. Humphreys BD, Lin S-L, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010;176:85–97. · DOI
  28. Inoue T, Okada H, Takenaka T, Watanabe Y, Suzuki H. A case report suggesting the occurrence of epithelial-mesenchymal transition in obstructive nephropathy. Clin Exp Nephrol. 2009;13:385–8. · DOI
  29. Mubarak KK, Montes-Worboys A, Regev D, Nasreen N, Mohammed KA, Faruqi I, et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J. 2012;39:133–40. · DOI
  30. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest. 2008;118:3331–42.
  31. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep. 2007;9:136–43. · DOI
  32. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;122:2756–62. · DOI · Paper page
  33. Wright JL, Tazelaar HD, Churg A. Fibrosis with emphysema. Histopathology. 2011;58:517–24. · DOI
  34. Bocchino M, Agnese S, Fagone E, Svegliati S, Grieco D, Vancheri C, et al. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS One. 2010;5:e14003. · DOI
  35. Schaberg T, Rau M, Stephan H, Lode H. Increased number of alveolar macrophages expressing surface molecules of the CD11/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells. Am Rev Respir Dis. 1993;147:1507–13. · DOI
  36. Ye Q, Dalavanga Y, Poulakis N, Sixt SU, Guzman J, Costabel U. Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis. Eur Respir J. 2008;31:1030–6. · DOI
  37. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med Camb Mass. 1994;1:71–81.
  38. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest. 2004;113:243–52. · DOI
  39. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol. 2004;16:733–8. · DOI
  40. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1. Am J Pathol. 2005;166:1321–32. · DOI
  41. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A. 2006;103:13180–5. · DOI · Paper page
  42. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2009;180:657–65. · DOI
  43. Fintha A, Gasparics Á, Rosivall L, Sebe A. Therapeutic targeting of fibrotic epithelial-mesenchymal transition–an outstanding challenge. Front Pharmacol. 2019;10:388. https://doi.org/10.3389/fphar.2019.00388. · DOI
  44. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108:E1475–83. · DOI
  45. Rout-Pitt N, Farrow N, Parsons D, Donnelley M. Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology. Respir Res. 2018;19:136. · DOI
  46. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110:341–50. · DOI
  47. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest Am Soc Clin Invest. 2003;112:1776–84. · DOI
  48. Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis–evidence for and against. Int J Exp Pathol. 2011;92:143–50. · DOI
  49. Kisseleva T, Brenner DA. Fibrogenesis of parenchymal organs. Proc Am Thorac Soc Am Thor Soc – PATS. 2008;5:338–42. · DOI
  50. Duffield JS, Humphreys BD. Origin of new cells in the adult kidney: results from genetic labeling techniques. Kidney Int. 2011;79:494–501. · DOI
  51. Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol. 2010;177:632–43. · DOI
  52. Sato Y, Yanagita M. Resident fibroblasts in the kidney: a major driver of fibrosis and inflammation. Inflamm Regen. 2017;37:17. · DOI
  53. Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80:309–26. · DOI
  54. Grande MT, Sánchez-Laorden B, López-Blau C, De Frutos CA, Boutet A, Arévalo M, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 2015;21:989–97. · DOI
  55. Hertig A, Anglicheau D, Verine J, Pallet N, Touzot M, Ancel P-Y, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol JASN. 2008;19:1584–91. · DOI
  56. Huang S, Susztak K. Epithelial plasticity versus EMT in kidney fibrosis. Trends Mol Med. 2016;22:4–6. · DOI
  57. Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121:3981–90. · DOI
  58. Paliege A, Rosenberger C, Bondke A, Sciesielski L, Shina A, Heyman SN, et al. Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int. 2010;77:312–8. · DOI
  59. Zhang Y, Zhu X, Huang X, Wei X, Zhao D, Jiang L, Zhao X, Du Y. Advances in understanding the effects of erythropoietin on renal fibrosis. Front Med. 2020;7:47. https://doi.org/10.3389/fmed.2020.00047. · DOI
  60. Fan X, Gaur U, Sun L, Yang D, Yang M. The growth differentiation factor 11 (GDF11) and myostatin (MSTN) in tissue specific aging. Mech Ageing Dev. 2017;164:108–12. · DOI
  61. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. Growth Factors Chur Switz. 2011;29:196–202. · DOI
  62. Graham-Brown MPM, Patel AS, Stensel DJ, March DS, Marsh A-M, McAdam J, McCann GP, Burton JO. Imaging of myocardial fibrosis in patients with end-stage renal disease: current limitations and future possibilities. Biomed Res Int 2017:e5453606. https:/doi.org/10.1155/2017/5453606. https://www.hindawi.com/journals/bmri/2017/5453606/ · DOI
  63. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225:631–7. · DOI · Paper page
  64. Rog-Zielinska EA, Norris RA, Kohl P, Markwald R. The living scar--cardiac fibroblasts and the injured heart. Trends Mol Med. 2016;22:99–114. · DOI
  65. Forte E, Furtado MB, Rosenthal N. The interstitium in cardiac repair: role of the immune–stromal cell interplay. Nat Rev Cardiol. Nature Publishing Group. 2018;15:601–16. · DOI
  66. Ma Z-G, Yuan Y-P, Wu H-M, Zhang X, Tang Q-Z. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14:1645–57. · DOI
  67. Chen WCW, Baily JE, Corselli M, Díaz ME, Sun B, Xiang G, et al. Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. Stem Cells Dayt Ohio. 2015;33:557–73. · DOI
  68. Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L. Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med. 2012;18:1262–70. · DOI · Paper page
  69. Chang Y, Li H, Guo Z. Mesenchymal stem cell-like properties in fibroblasts. Cell Physiol Biochem Int J Exp Cell PhysiolBiochem Pharmacol. 2014;34:703–14. · DOI
  70. Furtado MB, Nim HT, Boyd SE, Rosenthal NA. View from the heart: cardiac fibroblasts in development, scarring and regeneration. Development Oxford University Press for The Company of Biologists Limited. 2016;143:387–97. · DOI · Paper page
  71. Liu Y, Hu Z-F, Liao H-H, Liu W, Liu J, Ma Z-G, et al. Toll-like receptor 5 deficiency attenuates interstitial cardiac fibrosis and dysfunction induced by pressure overload by inhibiting inflammation and the endothelial-mesenchymal transition. Biochim Biophys Acta. 2015;1852:2456–66. · DOI
  72. Ranjan P, Kumari R, Verma SK. Cardiac fibroblasts and cardiac fibrosis: precise role of exosomes. Front Cell Dev Biol. 2019;7:318. https://doi.org/10.3389/fcell.2019.00318. · DOI
  73. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952–61. · DOI
  74. Fang M, Xiang F-L, Braitsch CM, Yutzey KE. Epicardium-derived fibroblasts in heart development and disease. J Mol Cell Cardiol. 2016;91:23–7. · DOI
  75. Ruiz-Villalba A, Simón AM, Pogontke C, Castillo MI, Abizanda G, Pelacho B, et al. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J Am Coll Cardiol. 2015;65:2057–66. · DOI
  76. Bersini S, Gilardi M, Mora M, Krol S, Arrigoni C, Candrian C, et al. Tackling muscle fibrosis: from molecular mechanisms to next generation engineered models to predict drug delivery. Adv Drug Deliv Rev. 2018;129:64–77. · DOI
  77. Mahdy MAA. Skeletal muscle fibrosis: an overview. Cell Tissue Res. 2019;375:575–88. · DOI
  78. Järvinen TA, Kääriäinen M, Järvinen M, Kalimo H. Muscle strain injuries. Curr Opin Rheumatol. 2000;12:155–61. · DOI
  79. Serrano AL, Muñoz-Cánoves P. Regulation and dysregulation of fibrosis in skeletal muscle. Exp Cell Res. 2010;316:3050–8. · DOI
  80. Delaney K, Kasprzycka P, Ciemerych MA, Zimowska M. The role of TGF-β1 during skeletal muscle regeneration. Cell Biol Int. 2017;41:706–15. · DOI
  81. Järvinen TAH, Józsa L, Kannus P, Järvinen TLN, Järvinen M. Organization and distribution of intramuscular connective tissue in normal and immobilized skeletal muscles. An immunohistochemical, polarization and scanning electron microscopic study. J Muscle Res Cell Motil. 2002;23:245–54. · DOI
  82. Murphy S, Ohlendieck K. The biochemical and mass spectrometric profiling of the dystrophin complexome from skeletal muscle. Comput Struct Biotechnol J. 2015;14:20–7. https://doi.org/10.1016/j.csbj.2015.11.002. · DOI
  83. Prazeres PHDM, Turquetti AOM, Azevedo PO, Barreto RSN, Miglino MA, Mintz A, et al. Perivascular cell αv integrins as a target to treat skeletal muscle fibrosis. Int J Biochem Cell Biol. 2018;99:109–13. · DOI
  84. Perandini LA, Chimin P, Lutkemeyer D d S, Câmara NOS. Chronic inflammation in skeletal muscle impairs satellite cells function during regeneration: can physical exercise restore the satellite cell niche? FEBS J. 2018;285:1973–84. · DOI
  85. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Phys Regul Integr Comp Phys. 2005;288:R345–53.
  86. Tidball JG, Welc SS. Macrophage-derived IGF-1 is a potent coordinator of myogenesis and inflammation in regenerating muscle. Mol Ther. 2015;23:1134–5. · DOI
  87. Braga TT, Agudelo JSH, Camara NOS. Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol. 2015;6:602. https://doi.org/10.3389/fimmu.2015.00602. · DOI
  88. Lemos DR, Babaeijandaghi F, Low M, Chang C-K, Lee ST, Fiore D, et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med. 2015;21:786–94. · DOI · Paper page
  89. Murray IR, Gonzalez ZN, Baily J, Dobie R, Wallace RJ, Mackinnon AC, et al. αv integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis. Nat Commun. 2017;8:1118. · DOI
  90. Cholok D, Lee E, Lisiecki J, Agarwal S, Loder S, Ranganathan K, et al. Traumatic muscle fibrosis: from pathway to prevention. J Trauma Acute Care Surg. 2017;82:174–84. · DOI
  91. Ciciliot S, Schiaffino S. Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr Pharm Des. 2010;16:906–14. · DOI
  92. Ding J, Tredget EE. Cellular and molecular mechanism of dermal fibrosis following burn injury, and exploration of therapeutic approaches. J Aesthetic Reconstr Surg. 2016;1:3. https://doi.org/10.4172/2472-1905.10003. · DOI
  93. Nejati R, Kovacic D, Slominski A. Neuro-immune-endocrine functions of the skin: an overview. Expert Rev Dermatol. 2013;8:581–3. · DOI
  94. Glim JE, van Egmond M, Niessen FB, Everts V, Beelen RHJ. Detrimental dermal wound healing: what can we learn from the oral mucosa? Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2013;21:648–60.
  95. Karppinen S-M, Heljasvaara R, Gullberg D, Tasanen K, Pihlajaniemi T. Toward understanding scarless skin wound healing and pathological scarring. F1000Research. 2019;8:787. · DOI
  96. Ridiandries A, Tan JTM, Bursill CA. The role of chemokines in wound healing. Int J Mol Sci. 2018;19(10):3217. https://doi.org/10.3390/ijms19103217. · DOI
  97. Su Y, Richmond A. Chemokine regulation of neutrophil infiltration of skin wounds. Adv Wound Care. 2015;4:631–40. · DOI
  98. Driskell RR, Watt FM. Understanding fibroblast heterogeneity in the skin. Trends Cell Biol. 2015;25:92–9. · DOI
  99. Ng CP, Hinz B, Swartz MA. Interstitial fluid flow induces myofibroblast differentiation and collagen alignment in vitro. J Cell Sci The Company of Biologists Ltd. 2005;118:4731–9. · DOI
  100. Vallée A, Lecarpentier Y. TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 2019;9:98. · DOI
  101. Jagadeesan J, Bayat A. Transforming growth factor beta (TGFβ) and keloid disease. Int J Surg. 2007;5:278–85. · DOI
  102. Cañedo-Dorantes L, Cañedo-Ayala M. Skin Acute Wound healing: a comprehensive review. Int J Inflam. 2019:e3706315. https://doi.org/10.1155/2019/3706315. https://www.hindawi.com/journals/iji/2019/3706315/ · DOI
  103. Marshall CD, Hu MS, Leavitt T, Barnes LA, Lorenz HP, Longaker MT. Cutaneous scarring: basic science, current treatments, and future directions. Adv Wound Care. 2018;7:29–45. · DOI
  104. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med Camb Mass. 2011;17:113–25.
  105. Lichtman MK, Otero-Vinas M, Falanga V. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2016;24:215–22.
  106. Ogawa R, Akaishi S, Kuribayashi S, Miyashita T. Keloids and hypertrophic scars can now be cured completely: recent progress in our understanding of the pathogenesis of keloids and hypertrophic scars and the most promising current therapeutic strategy. J Nippon Med Sch. 2016;83:46–53. · DOI
  107. Khansa I, Harrison B, Janis JE. Evidence-Based scar management: how to improve results with technique and technology. Plast Reconstr Surg. 2016;138:165S–78S. · DOI
  108. Luong VH, Chino T, Oyama N, Matsushita T, Sasaki Y, Ogura D, et al. Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. Arthritis Res Ther. 2018;20:46. · DOI
  109. Walton KL, Johnson KE, Harrison CA. Targeting TGF-β Mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol. 2017;8:461. https://doi.org/10.3389/fphar.2017.00461. · DOI
  110. Crafts TD, Jensen AR, Blocher-Smith EC, Markel TA. Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia. Cytokine. 2015;71:385–93. · DOI
  111. Zubair M, Ahmad J. Role of growth factors and cytokines in diabetic foot ulcer healing: a detailed review. Rev Endocr Metab Disord. 2019;20:207–17. · DOI
  112. Fallowfield JA, Kendall TJ, Iredale JP. Reversal of fibrosis: no longer a pipe dream? Clin Liver Dis. 2006;10:481–97. · DOI
  113. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. Elsevier. 2004;126:1740–9. · DOI
  114. Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol. Medknow Publications. 2009;15:72. · DOI
  115. Cordero-Espinoza L, Huch M. The balancing act of the liver: tissue regeneration versus fibrosis. J Clin Invest Am Soc Clin Invest. 2018;128:85–96. · DOI
  116. Ahmad A, Ahmad R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc. 2012;18:155–67. · DOI
  117. Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F.F1000Res. 20187:F1000 Faculty Rev-921. https://doi.org/10.12688/f1000research.14841.1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024236/ · DOI
  118. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatol Baltim Md. 2009;50:261–74. · DOI · Paper page
  119. Meijer C, Wiezer MJ, Diehl AM, Schouten HJ, Schouten HJ, Meijer S, et al. Kupffer cell depletion by CI2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy. Liver. 2000;20:66–77. · DOI
  120. Li Y, Lua I, French SW, Asahina K. Role of TGF-β signaling in differentiation of mesothelial cells to vitamin A-poor hepatic stellate cells in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2016;310:G262–72. · DOI
  121. Carpino G, Renzi A, Franchitto A, Cardinale V, Onori P, Reid L, Alvaro D, Gaudio E. Stem/progenitor cell niches involved in hepatic and biliary regeneration. Stem Cells Int. 2016;2016:3658013. https://doi.org/10.1155/2016/3658013. · DOI
  122. Köhn-Gaone J, Gogoi-Tiwari J, Ramm GA, Olynyk JK, Tirnitz-Parker JEE. The role of liver progenitor cells during liver regeneration, fibrogenesis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2016;310:G143–54. · DOI
  123. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608. · DOI
  124. Stål P. Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance. World J Gastroenterol: WJG. 2015;21:11077–87. · DOI
  125. Li S-N, Wu J-F. TGF-β/SMAD signaling regulation of mesenchymal stem cells in adipocyte commitment. Stem Cell Res Ther. 2020;11(1):41. https://doi.org/10.1186/s13287-020-1552-y. · DOI
  126. Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):a021873. https://doi.org/10.1101/cshperspect.a021873. · DOI · Paper page
  127. Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, et al. Bone morphogenetic protein (BMP) signaling in development and human diseases. Genes Dis. 2014;1:87–105. · DOI
  128. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258:7155–60. · DOI
  129. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A. 1981;78:5339–43. · DOI
  130. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783–810. · DOI
  131. Katagiri T, Watabe T. Bone morphogenetic proteins. Cold Spring Harb Perspect Biol. 2016;8:a021899. · DOI
  132. Ramirez H, Patel SB, Pastar I. The role of TGFβ signaling in wound epithelialization. Adv Wound Care. 2014;3:482–91. · DOI
  133. Akhurst RJ, Derynck R. TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001;11:S44–51.
  134. Nawshad A, Hay ED. TGFbeta3 signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation during mouse palate development. J Cell Biol. 2003;163:1291–301. · DOI
  135. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990;346:371–4. · DOI
  136. Jiménez SA, Castro SV, Piera-Velázquez S. Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. Curr Rheumatol Rev. 2010;6:283–94. · DOI
  137. Meng X-M, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38. · DOI · Paper page
  138. Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S, et al. TGF-β and fibrosis in different organs—molecular pathway imprints. Biochim Biophys Acta (BBA) - Mol Basis Dis. 1792;2009:746–56.
  139. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997;100:768–76. · DOI
  140. Goumenos DS, Tsamandas AC, Oldroyd S, Sotsiou F, Tsakas S, Petropoulou C, et al. Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron. 2001;87:240–8. · DOI
  141. Molina-Molina M, Serrano-Mollar A, Bulbena O, Fernandez-Zabalegui L, Closa D, Marin-Arguedas A, et al. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax. 2006;61:604–10. · DOI
  142. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int. 1999;56:1455–67. · DOI
  143. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab. 2000;71:418–35. · DOI
  144. Presser LD, McRae S, Waris G. Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion. PLoS ONE [Internet]. 2013 [cited 2020 May 25]; 8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578869/ · DOI
  145. Milani S, Herbst H, Schuppan D, Stein H, Surrenti C. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol. 1991;139:1221–9.
  146. Bernasconi P, Di Blasi C, Mora M, Morandi L, Galbiati S, Confalonieri P, et al. Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscul Disord NMD. 1999;9:28–33. · DOI
  147. Ferreira RR, da Silva Abreu R, Vilar-Pereira G, Degrave W, Meuser-Batista M, Ferreira NVC, et al. TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas’ heart disease. PLoS Negl Trop Dis. Public Library of Science. 2019;13:e0007602. · DOI
  148. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A. 1999;96:12719–24. · DOI
  149. Kim D-Y, Lee S-H, Fu Y, Jing F, Kim W-Y, Hong S-B, Song J-A, Choe H, Ryu HJ, Kim M, Lim D, Kim M-S, Yun C-O, et al. Del-1, an endogenous inhibitor of TGF-β activation, attenuates fibrosis. Front Immunol [Internet]. Frontiers; 2020 [cited 2020 Apr 30]; 11. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2020.00068/full · DOI
  150. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130–5. https://doi.org/10.1161/01.cir.0000020689.12472.e0. · DOI
  151. Wei Y, Kim TJ, Peng DH, Duan D, Gibbons DL, Yamauchi M, et al. Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis. J Clin Invest Am Soc Clin Invest. 2017;127:3675–88. · DOI
  152. Stone RC, Pastar I, Ojeh N, Chen V, Liu S, Garzon KI, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 2016;365:495–506. · DOI
  153. Bujor AM, Asano Y, Haines P, Lafyatis R, Trojanowska M. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum. 2011;63:1729–37. · DOI
  154. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res. 2008;57:274–82. · DOI
  155. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–84. · DOI
  156. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893–9. · DOI
  157. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev. 1992;32:160–7. · DOI
  158. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev. 1996;6:432–8. · DOI
  159. Wagner DO, Sieber C, Bhushan R, Börgermann JH, Graf D, Knaus P. BMPs: from bone to body morphogenetic proteins. Sci Signal. 2010;3:mr1.
  160. Herrera B, Addante A, Sánchez A. BMP Signalling at the crossroad of liver fibrosis and regeneration. Int J Mol Sci [Internet]. 2017 [cited 2020 May 7]; 19. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795989/ · DOI
  161. Weiskirchen R, Meurer SK. BMP-7 counteracting TGF-beta1 activities in organ fibrosis. Front Biosci. Landmark Ed. 2013;18:1407–34. · DOI
  162. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal. 2011;23:609–20. · DOI · Paper page
  163. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors Chur Switz. 2004;22:233–41. · DOI
  164. Jeffery TK, Upton PD, Trembath RC, Morrell NW. BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. Am J Physiol-Lung Cell Mol Physiol Am Physiol Soc. 2005;288:L370–8. · DOI
  165. Rivera-Feliciano J, Tabin CJ. Bmp2 instructs cardiac progenitors to form the heart-valve-inducing field. Dev Biol. 2006;295:580–8. · DOI
  166. Zhang H, Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development. The Company of Biologists Ltd. 1996;122:2977–86. · DOI
  167. Blázquez-Medela AM, Jumabay M, Boström KI. Beyond the Bone: bone morphogenetic protein (BMP) signaling in adipose tissue. Obes Rev Off J Int Assoc Study Obes. 2019;20:648–58. · DOI
  168. Jin W, Takagi T, Kanesashi S, Kurahashi T, Nomura T, Harada J, et al. Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins. Dev Cell. 2006;10:461–71. · DOI
  169. Gerjevic LN, Liu N, Lu S, Harrison-Findik DD. Alcohol activates TGF-beta but inhibits BMP receptor-mediated Smad signaling and Smad4 binding to hepcidin promoter in the liver. Int J Hepatol [Internet]. 2012 [cited 2020 May 7]; 2012. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202137/ · DOI
  170. Nakatsuka R, Taniguchi M, Hirata M, Shiota G, Sato K. Transient expression of bone morphogenic protein-2 in acute liver injury by carbon tetrachloride. J Biochem (Tokyo). 2006;141(1):113–9. https://doi.org/10.1093/jb/mvm012. · DOI
  171. Shen H, Huang G, Hadi M, Choy P, Zhang M, Minuk GY, et al. Transforming growth factor-β1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol-Gastrointest Liver Physiol Am Physiol Soc. 2003;285:G539–46.
  172. Wang S, Sun A, Li L, Zhao G, Jia J, Wang K, et al. Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex. J Cell Mol Med. 2012;16:2301–10. · DOI
  173. Yang Y-L, Ju H-Z, Liu S-F, Lee T-C, Shih Y-W, Chuang L-Y, et al. BMP-2 suppresses renal interstitial fibrosis by regulating epithelial–mesenchymal transition. J Cell Biochem. 2011;112:2558–65. · DOI
  174. Yang Y-L, Liu Y-S, Chuang L-Y, Guh J-Y, Lee T-C, Liao T-N, et al. Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type i transforming growth factor-β receptors. Endocrinology. Oxford Academic. 2009;150:727–40. · DOI
  175. De Langhe E, Cailotto F, De Vooght V, Aznar-Lopez C, Vanoirbeek JA, Luyten FP, Lories RJU. Enhanced endogenous bone morphogenetic protein signaling protects against bleomycin induced pulmonary fibrosis. Respir Res [Internet]. 2015 [cited 2020 May 25]; 16. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364322/ · DOI
  176. Shlyonsky V, Soussia IB, Naeije R, Mies F. Opposing effects of bone morphogenetic protein-2 and endothelin-1 on lung fibroblast chloride currents. Am J Respir Cell Mol Biol. 2011;45(6):1154–60. https://doi.org/10.1165/rcmb.2010-0443OC. · DOI
  177. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. Public Library of Science. 2008;5:e62. · DOI
  178. Gao X, Cao Y, Yang W, Duan C, Aronson JF, Rastellini C, et al. BMP2 inhibits TGF-β-induced pancreatic stellate cell activation and extracellular matrix formation. Am J Physiol Gastrointest Liver Physiol. 2013;304:G804–13. · DOI
  179. Gao X, Cao Y, Staloch DA, Gonzales MA, Aronson JF, Chao C, et al. Bone morphogenetic protein signaling protects against cerulein-induced pancreatic fibrosis. PLoS One. 2014;9:e89114. · DOI
  180. Liu W, Selever J, Wang D, Lu M-F, Moses KA, Schwartz RJ, et al. Bmp4 signaling is required for outflow-tract septation and branchial-arch artery remodeling. Proc Natl Acad Sci. National Academy of Sciences. 2004;101:4489–94. · DOI
  181. Selever J, Liu W, Lu M-F, Behringer RR, Martin JF. Bmp4 in limb bud mesoderm regulates digit pattern by controlling AER development. Dev Biol. 2004;276:268–79. · DOI
  182. Zhang Y, Zhang Z, Zhao X, Yu X, Hu Y, Geronimo B, et al. A new function of BMP4: dual role for BMP4 in regulation of Sonic hedgehog expression in the mouse tooth germ. Development. The Company of Biologists Ltd. 2000;127:1431–43. · DOI
  183. Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995;9:2105–16. · DOI
  184. Lawson KA, Dunn NR, Roelen BAJ, Zeinstra LM, Davis AM, Wright CVE, et al. Bmp4 is required for the generation of primordial germ cells in the mouse embryo. Genes Dev. 1999;13:424–36. · DOI
  185. Molloy EL, Adams A, Moore JB, Masterson JC, Madrigal-Estebas L, Mahon BP, et al. BMP4 induces an epithelial–mesenchymal transition-like response in adult airway epithelial cells. Growth Factors. Taylor & Francis. 2008;26:12–22. · DOI
  186. Pegorier S, Campbell GA, Kay AB, Lloyd CM. Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-β1 in normal human lung fibroblasts (NHLF). Respir Res. 2010;11:85. · DOI
  187. Yao M, Li J, Yuan S, Zhu X, Hu Z, Li Q, et al. Role of the arecoline/YAP1/BMP4 pathway in promoting endothelial-mesenchymal transition in oral submucous fibrosis. J Oral Pathol Med. 2020;49:305–10. · DOI
  188. Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, et al. Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. J Gastroenterol. 2019;54:1007–18. · DOI
  189. Omar R, Yang J, Alrushaid S, Burczynski FJ, Minuk GY, Gong Y. Inhibition of BMP4 and alpha smooth muscle actin expression in LX-2 hepatic stellate cells by BMP4-siRNA lipid based nanoparticle. J Pharm Pharm Sci. 2018;21:119–34. · DOI
  190. Fan J, Shen H, Sun Y, Li P, Burczynski F, Namaka M, et al. Bone morphogenetic protein 4 mediates bile duct ligation induced liver fibrosis through activation of Smad1 and ERK1/2 in rat hepatic stellate cells. J Cell Physiol. 2006;207:499–505. · DOI
  191. Lu J-W, Hsia Y, Yang W-Y, Lin Y-I, Li C-C, Tsai T-F, et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis. 2012;33:209–19. · DOI
  192. Zhong W, Shen W-F, Ning B-F, Hu P-F, Lin Y, Yue H-Y, et al. Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatol Baltim Md. 2009;50:1524–36. · DOI
  193. Azibani F, Fazal L, Chatziantoniou C, Samuel J-L, Delcayre C. La fibrose dans l’hypertension artérielle : une histoire d’équilibre. Ann Cardiol Angeiol. 2012;61:150–5. · DOI
  194. Sun B, Huo R, Sheng Y, Li Y, Xie X, Chen C, et al. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension. 2013;61:352–60. · DOI
  195. Tominaga T, Abe H, Ueda O, Goto C, Nakahara K, Murakami T, et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J Biol Chem. 2011;286:20109–16. · DOI
  196. Kluk MW, Ji Y, Shin EH, Amrani O, Onodera J, Jackson WM, et al. Fibroregulation of mesenchymal progenitor cells by BMP-4 after traumatic muscle injury. J Orthop Trauma. 2012;26:693–8. · DOI
  197. de Mara CS, Duarte ASS, Sartori-Cintra AR, Luzo ACM, Saad STO, Coimbra IB. Chondrogenesis from umbilical cord blood cells stimulated with BMP-2 and BMP-6. Rheumatol Int. 2013;33:121–8. · DOI
  198. Hughes FJ, Collyer J, Stanfield M, Goodman SA. The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology. 1995;136:2671–7. · DOI
  199. Ye F, Xu H, Yin H, Zhao X, Li D, Zhu Q, et al. The role of BMP6 in the proliferation and differentiation of chicken cartilage cells. PLoS One. Public Libr Sci. 2019;14:e0204384. · DOI
  200. Sugiura K, Su Y-Q, Eppig JJ. Does bone morphogenetic protein 6 (BMP6) affect female fertility in the mouse? Biol Reprod. Oxford Academic. 2010;83:997–1004. · DOI

200 of 315 shown

Cited by

Sorted by citations

See all 28

Metadata

Authors
Frohlich, J., & Vinciguerra, M.
ORCID
Vinciguerra, Manlio
Venue
GeroScience
Publisher
Springer Science and Business Media LLC
Published
2020-10-06
Volume
42
Issue
6
Pages
1475-1498
ISSN
  • 2509-2715
  • 2509-2723
DOI
10.1007/s11357-020-00279-w
Cited by
28
References
19
Language
en
Licence
Funders
European Social Fund and European Regional Development Fund (CZ.02.1.01/0.0/0.0/15_003/0000492)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review